Key result
Platelet function assays yield variable high on-treatment platelet reactivity rates to aspirin in cerebrovascular disease.
Why the study?
The prevalence of high on-treatment platelet reactivity to aspirin in adults with carotid atherosclerosis or ischemic stroke, its dependence on the platelet function assay used, and its associations with clinical outcomes and pharmacogenetic determinants required systematic synthesis.
Meta-Analysis
Answers are grounded in this paper and cite their sources.
Retrospective registration limits transparency; reinforces need for prospective PROSPERO registration in future meta-analyses.
Retrospective registration of a completed systematic review and meta-analysis. The review was not prospectively registered. The original written protocol (version 1.0, created on 29 May 2026 before the database searches were run that day, but not registered or shared at that time) is attached unchanged, together with a dated log of all amendments and the analysis plan as conducted. A PROSPERO submission (12 June 2026) was never approved by the full review team and was cancelled; it was not registered. Question: in adults with carotid atherosclerosis or ischemic stroke taking aspirin, what is the prevalence of high on-treatment platelet reactivity (HTPR, "aspirin resistance"), and how much does it depend on the platelet function assay used? Secondary questions: association of HTPR with clinical and imaging outcomes, and pharmacogenetic determinants of aspirin response. Prevalence was pooled with a random-intercept logistic generalized linear mixed model, stratified by assay platform; outcomes and genetic associations were synthesized narratively.
No takes yet. Share an insight, caveat, or question.
Enrico Pirani (2026) conducted a meta-analysis in Carotid atherosclerosis or ischemic stroke. High on-treatment platelet reactivity (HTPR) to aspirin vs. Normal on-treatment platelet reactivity / assay platforms was evaluated on Prevalence of high on-treatment platelet reactivity (HTPR) to aspirin stratified by platelet function assay platform. High on-treatment platelet reactivity to aspirin in carotid atherosclerosis or ischemic stroke was evaluated by assay platform in this retrospective registration without reported numerical results.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: